BioCardia, Inc. (NASDAQ:BCDA – Get Free Report) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 151,200 shares, a decrease of 91.7% from the August 31st total of 1,830,000 shares. Based on an average trading volume of 824,700 shares, the short-interest ratio is presently 0.2 days. Approximately 6.4% of the shares of the stock are short sold.
Analyst Ratings Changes
Separately, HC Wainwright upped their target price on BioCardia from $4.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, August 16th.
View Our Latest Report on BioCardia
BioCardia Stock Performance
BioCardia (NASDAQ:BCDA – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.78). BioCardia had a negative return on equity of 3,638.68% and a negative net margin of 1,999.77%. On average, sell-side analysts predict that BioCardia will post -5.06 earnings per share for the current year.
About BioCardia
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Read More
- Five stocks we like better than BioCardia
- What is Put Option Volume?
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- 3 Fintech Stocks With Good 2021 Prospects
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- What is the Euro STOXX 50 Index?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.